BiotechTube

Prednisone + Jakavi(ruxolitinib) + Prednisone

Phase 2Recruiting
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

GVHD - Graft-Versus-Host Disease

Conditions

GVHD - Graft-Versus-Host Disease, Neoplasms, Haematopoietic Stem Cell Transplantation

Trial Timeline

Jan 15, 2025 → Aug 31, 2029

NCT ID
NCT06756061

About Prednisone + Jakavi(ruxolitinib) + Prednisone

Prednisone + Jakavi(ruxolitinib) + Prednisone is a phase 2 stage product being developed by Novartis for GVHD - Graft-Versus-Host Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06756061. Target conditions include GVHD - Graft-Versus-Host Disease, Neoplasms, Haematopoietic Stem Cell Transplantation.

What happened to similar drugs?

0 of 5 similar drugs in GVHD - Graft-Versus-Host Disease were approved

Approved (0) Terminated (0) Active (5)
🔄Alpha-1 antitrypsin (AAT) + PlaceboCSLPhase 3
🔄Tacrolimus (Tac) + Methotrexate (MTX) + Ruxolitinib (Rux) + Cyclophosphamide + Mycophenolate mofetil (MMF)IncytePhase 3
🔄Itacitinib + Placebo + Prednisone + MethylprednisoloneIncytePhase 3
🔄Ruxolitinib + Extracorporeal photopheresis (ECP) + Low-dose methotrexate (MTX) + Mycophenolate mofetil (MMF) + mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus) + Infliximab + Rituximab + Pentostatin + Imatinib + IbrutinibIncytePhase 3
🔄remestemcel-LMesoblastPhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06756061Phase 2Recruiting

Competing Products

19 competing products in GVHD - Graft-Versus-Host Disease

See all competitors
ProductCompanyStageHype Score
RituximabRochePhase 2
31
Efavaleukin AlfaAmgenPhase 1/2
24
AMG 592AmgenPhase 1
29
AMG 592AmgenPhase 1
29
milatuzumabGilead SciencesPhase 1
21
Itacitinib + Prednisone + MethylprednisoloneInnovent BiologicsPhase 1/2
24
Cyclophosphamide + abatacept + Methotrexate + TacrolimusBristol Myers SquibbPhase 2
35
ALD518 + ALD518 + ALD518CSLPhase 1/2
24
Alpha-1 antitrypsin (AAT) + PlaceboCSLPhase 3
40
Tacrolimus (Tac) + Methotrexate (MTX) + Ruxolitinib (Rux) + Cyclophosphamide + Mycophenolate mofetil (MMF)IncytePhase 3
44
RuxolitinibIncytePre-clinical
23
Itacitinib + Placebo + Prednisone + MethylprednisoloneIncytePhase 3
37
Ruxolitinib + PrednisoneIncytePhase 2
39
Itacitinib (200 mg) + Itacitinib (300 mg) + prednisone or methylprednisolone (corticosteroids)IncytePhase 1
26
Ruxolitinib + Extracorporeal photopheresis (ECP) + Low-dose methotrexate (MTX) + Mycophenolate mofetil (MMF) + mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus) + Infliximab + Rituximab + Pentostatin + Imatinib + IbrutinibIncytePhase 3
37
Ruxolitinib + Prednisone or methylprednisoloneIncytePhase 2
32
RuxolitinibIncytePre-clinical
23
Itacitinib + TocilizumabIncytePhase 1
18
remestemcel-LMesoblastPhase 3
34